Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Boston Scientific's Voraxaze's MAA Accepted by EMA for Review
by Zacks Equity Research
Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
EPA Validates NEOGEN's Disinfectant for Use Against COVID-19
by Zacks Equity Research
NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.
Omnicell, Pharmaceutical Strategies Enter Acquisition Deal
by Zacks Equity Research
Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.
5 Top-Ranked Dividend Growth Stocks Still At Bargain Prices
by Sweta Killa
Stocks that have a strong history of dividend growth, as opposed to those that offer high yields, form a healthy portfolio with more scope for capital appreciation.
Here's Why You Should Hold on to Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.
Baxter (BAX) Receives EUA for Regiocit Replacement Solution
by Zacks Equity Research
Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)
by Zacks Equity Research
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.
Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated
by Zacks Equity Research
Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Accuray (ARAY) registered decline in Product and Service revenues in Q4
Medtronic (MDT) Plans $160 Million R&D Investment in India
by Zacks Equity Research
The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.
HMS Holdings (HMSY) Loses 2.9% Since Q2 Earnings Release
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB segment in Q2.
Medtronic Plans New Acquisition in AI-Driven Diabetes Care
by Zacks Equity Research
Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.
Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.
Chemed's (CHE) VITAS Business Strong Amid Coronavirus Crisis
by Zacks Equity Research
Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.
National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat
by Zacks Equity Research
Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.
AMN Healthcare (AMN) Loses 3.3% Despite Q2 Earnings Beat
by Zacks Equity Research
AMN Healthcare (AMN) gained from two of its three core operating segments in Q2.
Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.
PRA Health (PRAH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.
Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up
by Zacks Equity Research
Insulet's (PODD) total Omnipod product line comes up with record revenue growth.
Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.